Skip to main content

PERSPECTIVE article

Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1516725

Reframing risks in rare diseases: Economics of networks, spillovers, and scale

Provisionally accepted
Carlisle Ford Runge Carlisle Ford Runge 1*James Campbell James Campbell 1Carlisle P Runge Carlisle P Runge 2
  • 1 University of Minnesota Twin Cities, St. Paul, United States
  • 2 Biomedical Advanced Research and Development Authority (BARDA), Washington, Maine, United States

The final, formatted version of the article will be published soon.

    Rare diseases affect over three hundred million individuals globally. Investment in research and development remains incommensurate with the challenges rare diseases pose. Further investment in information sharing platforms to promote common and standardized network technologies for rare disease is needed. Rare disease R&D generates information and assets that spill over in other ways, providing benefits that may not be apparent to investors ex ante.Analytical and computational methods recently applied at scale are promising. One important way of achieving efficiencies of scale in R&D is clustering rare diseases into groups with similar traits

    Keywords: Rare Diseases, Economics, networks, spillovers, scale, clustering

    Received: 31 Oct 2024; Accepted: 27 Nov 2024.

    Copyright: © 2024 Runge, Campbell and Runge. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Carlisle Ford Runge, University of Minnesota Twin Cities, St. Paul, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.